Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
05
2022
accepted:
08
08
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
The recently emerged SARS-CoV-2 Omicron variant exhibits several mutations on the spike protein, enabling it to escape the immunity elicited by natural infection or vaccines. Avidity is the strength of binding between an antibody and its specific epitope. The SARS-CoV-2 spike protein binds to its cellular receptor with high affinity and is the primary target of neutralizing antibodies. Therefore, protective antibodies should show high avidity. This study aimed at investigating the avidity of receptor-binding domain (RBD) binding antibodies and their neutralizing activity against the Omicron variant in SARS-CoV-2 infected patients and vaccinees. Samples were collected from 42 SARS-CoV-2 infected patients during the first pandemic wave, 50 subjects who received 2 doses of mRNA vaccine before the Omicron wave, 44 subjects who received 3 doses of mRNA vaccine, and 35 subjects who received heterologous vaccination (2 doses of adenovirus-based vaccine plus mRNA vaccine) during the Omicron wave. Samples were tested for the avidity of RBD-binding IgG and neutralizing antibodies against the wild-type SARS-CoV-2 virus and the Omicron variant. In patients, RBD-binding IgG titers against the wild-type virus increased with time, but remained low. High neutralizing titers against the wild-type virus were not matched by high avidity or neutralizing activity against the Omicron variant. Vaccinees showed higher avidity than patients. Two vaccine doses elicited the production of neutralizing antibodies, but low avidity for the wild-type virus; antibody levels against the Omicron variant were even lower. Conversely, 3 doses of vaccine elicited high avidity and high neutralizing antibodies against both the wild-type virus and the Omicron variant. Repeated vaccination increases antibody avidity against the spike protein of the Omicron variant, suggesting that antibodies with high avidity and high neutralizing potential increase cross-protection against variants that carry several mutations on the RBD.
Sections du résumé
Background
UNASSIGNED
The recently emerged SARS-CoV-2 Omicron variant exhibits several mutations on the spike protein, enabling it to escape the immunity elicited by natural infection or vaccines. Avidity is the strength of binding between an antibody and its specific epitope. The SARS-CoV-2 spike protein binds to its cellular receptor with high affinity and is the primary target of neutralizing antibodies. Therefore, protective antibodies should show high avidity. This study aimed at investigating the avidity of receptor-binding domain (RBD) binding antibodies and their neutralizing activity against the Omicron variant in SARS-CoV-2 infected patients and vaccinees.
Methods
UNASSIGNED
Samples were collected from 42 SARS-CoV-2 infected patients during the first pandemic wave, 50 subjects who received 2 doses of mRNA vaccine before the Omicron wave, 44 subjects who received 3 doses of mRNA vaccine, and 35 subjects who received heterologous vaccination (2 doses of adenovirus-based vaccine plus mRNA vaccine) during the Omicron wave. Samples were tested for the avidity of RBD-binding IgG and neutralizing antibodies against the wild-type SARS-CoV-2 virus and the Omicron variant.
Results
UNASSIGNED
In patients, RBD-binding IgG titers against the wild-type virus increased with time, but remained low. High neutralizing titers against the wild-type virus were not matched by high avidity or neutralizing activity against the Omicron variant. Vaccinees showed higher avidity than patients. Two vaccine doses elicited the production of neutralizing antibodies, but low avidity for the wild-type virus; antibody levels against the Omicron variant were even lower. Conversely, 3 doses of vaccine elicited high avidity and high neutralizing antibodies against both the wild-type virus and the Omicron variant.
Conclusions
UNASSIGNED
Repeated vaccination increases antibody avidity against the spike protein of the Omicron variant, suggesting that antibodies with high avidity and high neutralizing potential increase cross-protection against variants that carry several mutations on the RBD.
Identifiants
pubmed: 36093434
doi: 10.1155/2022/4813199
pmc: PMC9453088
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Synthetic
0
Viral Vaccines
0
mRNA Vaccines
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4813199Informations de copyright
Copyright © 2022 Francesca Dapporto et al.
Déclaration de conflit d'intérêts
F.D., A.M., and P.P. are employed by VisMederi Srl. M.L., E. Molesti are employed by VisMederi Research Srl. E. Montomoli is an external consultant and Chief Scientific Officer of VisMederi Srl and VisMederi Research Srl.
Références
NPJ Vaccines. 2021 Aug 16;6(1):104
pubmed: 34400651
J Infect Dis. 2022 May 4;225(9):1533-1544
pubmed: 33534885
Int J Infect Dis. 2021 May;106:61-64
pubmed: 33713819
PLoS One. 2021 Jul 2;16(7):e0253977
pubmed: 34214116
Viruses. 2022 Mar 16;14(3):
pubmed: 35337024
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
Biochem Biophys Res Commun. 2022 Jan 29;590:34-41
pubmed: 34968782
Sci Rep. 2020 Nov 18;10(1):20048
pubmed: 33208819
Viruses. 2021 Jul 12;13(7):
pubmed: 34372553
Acta Clin Belg. 2022 Jun;77(3):653-657
pubmed: 34152944
J Immunol Methods. 2021 Feb;489:112937
pubmed: 33253698
Vaccine. 2017 Jan 3;35(1):191-198
pubmed: 27789145
J Med Virol. 2021 May;93(5):3092-3104
pubmed: 33565617
Clin Infect Dis. 2008 Jan 15;46(2):186-92
pubmed: 18171249
Annu Rev Immunol. 2012;30:429-57
pubmed: 22224772
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
J Immunol Methods. 2017 Aug;447:31-36
pubmed: 28433580
Viruses. 2021 Jan 14;13(1):
pubmed: 33466921
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
PLoS Biol. 2018 Aug 10;16(8):e2006601
pubmed: 30096134
BMJ. 2021 Dec 20;375:n3105
pubmed: 34930779
Front Immunol. 2021 Jul 12;12:701501
pubmed: 34322129
Science. 2022 Feb 11;375(6581):678-680
pubmed: 35040667
Allergy. 2022 Aug;77(8):2381-2392
pubmed: 35124800
Sci Rep. 2021 Sep 3;11(1):17642
pubmed: 34480056
Vaccines (Basel). 2021 Jun 18;9(6):
pubmed: 34207300
J Med Virol. 2022 Jan;94(1):186-196
pubmed: 34427932
J Med Virol. 2021 Dec;93(12):6765-6777
pubmed: 34387884
J Virol Methods. 2021 Nov;297:114261
pubmed: 34403775